Cadrenal Therapeutics (CVKD) had its price target lowered by HC Wainwright from $32.00 to $13.00. They now have a "buy" rating on the stock.
Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting
Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes
Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion [Yahoo! Finance]
Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion